1 / 19

Where Angels Feared to Tread

????????????. Where Angels Feared to Tread. Roger Ashby Hunter-Fleming Ltd. Technology Transfer. Experience from both sides Hunter-Fleming, an example Working with universities. HUNTER FLEMING. PHARMACEUTICAL PIPELINE PROVIDERS.  Hunter-Fleming Ltd. Mission.

jaden
Download Presentation

Where Angels Feared to Tread

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ???????????? Where Angels Feared to Tread Roger Ashby Hunter-Fleming Ltd

  2. Technology Transfer • Experience from both sides • Hunter-Fleming, an example • Working with universities

  3. HUNTER FLEMING PHARMACEUTICAL PIPELINE PROVIDERS  Hunter-Fleming Ltd

  4. Mission To be a leading, highly profitable, international company supplying novel breakthrough prescription medicines to global marketing companies, in areas of significant unmet medical needs. PATENT TO PATIENT  Hunter-Fleming Ltd

  5. The Market  Hunter-Fleming Ltd

  6. Management • Giles Vardy, Non Exec Chairman, Chairman of AIM Steering Group, former CEO of Greig Middleton, Chairman CQS Management, alternative asset management business • Dr Jim Murray, CEO: co-founder of Shire, 29 years in Pharma industry • Professor Ernst Wulfert, CSO: former Research Director UCB responsible for the development of three blockbuster drugs – Keppra, Zyrtec, enofibrate • Dr. John Fox, Managing Director: Head of Planning at Shire, 20 years in pharmacology & clinical research • Neil Hockaday, FD: COO HSBC Corporate Banking  Hunter-Fleming Ltd

  7. University Collaborations • Bristol • Belfast • Southampton • St Marianna Hospital, Medical School, Kawasaki • Loyola, Chicago • CNAM, Paris • Kyoto Pharmaceutical University, Japan • Tromso, Norway • Strathclyde/Glasgow  Hunter-Fleming Ltd

  8. Business Model VALUE C NDA, drug filing B “Innovations Break Point” A Basic Discovery COST Basic Research ACADEMIA Innovation HF Drug Development BIG PHARMA  Hunter-Fleming Ltd

  9. IntegratedTherapies anti-neurodegenerative drugs (brain inflammatory diseases)HF 0220 Neurosciences (neurodegenerative diseases, AD, PD, stroke, MS…) Immunology & Inflammation (RA, Type I diabetes, asthma, rhinitis, cancer..) Cardiovascular & Metabolic Disorders (CHD, MI, Diabetes…) Novel cytoprotective drugs brain, heart, kidney HF 0220 “follow-ups” Anti-diabetic HF 1020  Hunter-Fleming Ltd

  10. Portfolio  Hunter-Fleming Ltd

  11. WHY ? • Access to blue sky research • Access to intellectual property • Access to ongoing research output

  12. FACT • British Telecom research spend £30m pa • Bristol University, - • UCL, Imperial College, - £500m pa • Southampton University -

  13. ACADEMIA Solutions seeking applications

  14. INDUSTRY Paucity of innovative knowledge cf Pharma 50% all new medicines in-licensed

  15. KEY ISSUES • Point of contact • Executive authority • Ability to deliver – Willing scientists • - Secured IP • Continuity

  16. Deal Breakers • Valuation of IP and / or Know how • Limitation of management expertise

  17. Decision • Licence OR • Start up new company

  18. Hunter-Fleming • Mature management team • Proven track record • Understand university’s modus operandi • Enduring partnership • Virtual circle taking IP to market • Financial returns to all- University • - Research Staff • - H-F shareholders

More Related